论文部分内容阅读
为了评价肾移植术后单独应用环孢素(CsA)是否优于其他免疫抑制方案,他们从1987.3～1989.8对151例肾移植受者随机分为单用CsA组(Ⅰ组,74例)和三联治疗组(Ⅱ组,77例)进行前瞻性试验。Ⅰ组免疫抑制方案:CsA5mg/kg.d静点,4天后按起始剂量15mg/kg.d口服,每3周递减2mg/kg.d,至大约5mg/kg.d时维持,保持CsA全血谷值浓度200～600ng/ml之间(RIA法),若发生2次以上急性排斥或血肌酐进行性升高者加用甲基强的松龙(MP),起始剂量按.8～16mg/d,以后8mg/d维持。Ⅱ组免疫抑制方案:术后头4天CsA按4mg/
In order to evaluate whether cyclosporine alone (CsA) is better than other immunosuppressive regimens after renal transplantation, 151 renal transplant recipients from 1987.3 to 1989.8 were randomly divided into single CsA group (group Ⅰ, n = 74) Treatment group (Ⅱ group, 77 cases) were prospectively tested. Group Ⅰ immunosuppressive regimen: CsA5mg / kg.d static point, 4 days after the initial dose of 15mg / kg.d orally, every 3 weeks decreased 2mg / kg.d, to about 5mg / kg.d maintain, keep CsA all Blood cereal concentration between 200 ~ 600ng / ml (RIA method), if more than 2 times acute rejection or progressive increase in serum creatinine plus methylprednisolone (MP), the initial dose by .8 ~ 16mg / d, after 8mg / d maintained. Group Ⅱ immunosuppression program: the first 4 days after CsA 4mg /